中国小分子药物领域对外授权最高纪录。来源|医药研究社最近,阿斯利康一笔巨款“砸”向加科思,引发了热议。据加科思发布的公告,其非全资附属公司与阿斯利康订立了许可与合作协议。根据协议,阿斯利康将获授予一项独家许可,以在全球范围(除中国外)研究、开发、注册、制造及商业化泛KRAS(鼠类肉瘤病毒癌基因,一种在许多人类癌症中发现的常见基因突变)抑制剂JAB-23E73,并须根据许可及合作协议负责与其进一步...
Source Link中国小分子药物领域对外授权最高纪录。来源|医药研究社最近,阿斯利康一笔巨款“砸”向加科思,引发了热议。据加科思发布的公告,其非全资附属公司与阿斯利康订立了许可与合作协议。根据协议,阿斯利康将获授予一项独家许可,以在全球范围(除中国外)研究、开发、注册、制造及商业化泛KRAS(鼠类肉瘤病毒癌基因,一种在许多人类癌症中发现的常见基因突变)抑制剂JAB-23E73,并须根据许可及合作协议负责与其进一步...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.